- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 64,76 | +1,50 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| CSPC PHARMA | 0,770 | -2,96 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. | ||
| SELLAS LIFE SCIENCES | 7,160 | +3,17 % | Sellas Life Sciences: 28,7 Mio. US-Dollar aus Optionsscheinausübung stärken Bilanz | ||
| MADRIGAL PHARMACEUTICALS | 409,10 | +0,94 % | AKTIONÄR-Tipp Madrigal: Positive News - Aktie steigt wieder | Die Aktie von Madrigal Pharmaceuticals hat zuletzt eine kurze Schwächephase erlebt. Diese hat das Papier aber nun bereits wieder ausgemerzt. Unterstützung erhält die Aktie dabei von positiven News von... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,260 | -2,95 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,100 | -0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| OPUS GENETICS | 3,520 | +0,57 % | Opus Genetics, Inc.: Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product | Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
| SAVARA | 4,587 | +4,42 % | Savara CFO to step down | ||
| GALECTIN THERAPEUTICS | 2,060 | +0,98 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 3,260 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| CGN MINING | 0,332 | +5,06 % | CGN MINING (01164): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE MATTERS RELATING TO RULE 13.92(2) OF THE LISTING RULES | ||
| PHOTOCURE | 5,200 | -1,89 % | Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics | OSLO, Norway, June 4, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, today announced the signing and successful completion... ► Artikel lesen | |
| ARCTICZYMES TECHNOLOGIES | 1,870 | +0,54 % | ArcticZymes Technologies ASA: ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch, Supporting Diversification into RNA and Continued Leadership in Cell & Gene Therapy | ||
| NEURIZON THERAPEUTICS | 0,030 | 0,00 % | Biocurious: Ahead of this year's Big Freeze, Neurizon hopes to 'do it for Daniher' |
NATTOPHARMA ASA gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NATTOPHARMA ASA finden Sie auf Wallstreet Online.